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ABSTRACT
Rapid Adaptation of Dopamine D2 Receptor Responses
in the Brain and Blood Following Acute
Ethanol
Ryan John Folsom
Department of Physiology and Developmental Biology, BYU
Master of Science in Neuroscience
Dopamine (DA) D2 receptor expression parallels DA levels in the brain and these
autoreceptors have been shown to be modulated by long-term ethanol exposure. We have
previously demonstrated that ventral tegmental area (VTA) GABA neurons also express D2
autoreceptors (D2R), and that DA and D2R agonists markedly enhance the excitability of VTA
GABA neurons, opposite to their well-known auto-receptor inhibition of DA neurons. Most
importantly, D2R antagonists block ethanol inhibition of VTA GABA neurons and D2R
expression in VTA GABA neurons down-regulates with chronic ethanol, as others have shown
for whole VTA D2R expression.
The aim of this study was to evaluate short-term D2R adaptation in specific brain reward
regions i.e., ventral tegmental area (VTA), nucleus accumbens (NAc), temporal lobe cortex, and
also in peripheral white blood cells (WBCs) as a potential biomarker for brain DA. To
accomplish these studies, we used quantitative RT-PCR to analyze rapid (within 2 hrs) changes
in D2R expression from both brain and blood samples of rats from one of four in vivo treatment
groups: saline, ethanol (2.5 g/kg, IP), eticlopride (1 mg/kg, IV), or quinpirole (0.1 mg/kg, IV). To
verify the qRT-PCR effect we observed from tissue punches of the selected brain regions, we
used immunofluorescence to quantify changes in D2R expression between the four treatment
groups. To determine whether D2R adaptation in the blood was dependent on communication
with the brain, we extracted blood samples and performed the same type of in vivo experiments
in vitro.
We found that D2R expression was increased in the VTA with ethanol, eticlopride and
quinpirole, increased in the NAc with ethanol but decreased with eticlopride and quinpirole, and
decreased with ethanol and quinpirole in the temporal lobe cortex. In the in vivo blood
experiments, D2R expression decreased in WBCs in all three drug treatment groups. In vitro
blood experiments showed increased expression with ethanol treatment and decreased with
eticlopride. When compared to saline treated animals, the immunofluorescence in the VTA
suggests that D2R expression increased in ethanol and eticlopride, but decreased in quinpirole
treated animals.
At this point, it is clear that D2R expression shows rapid adaptation when exposed to
acute doses of ethanol and D2 targeting drugs in both the brain and blood. More evidence is
needed through in vitro studies to determine whether a specific neuro-immune interaction is
directing the changes seen in the blood and whether or not chronically exposed animals show
significantly decreased D2R expression in the blood.
Keywords: ethanol, eticlopride, D2 dopamine receptor, VTA, NAc
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INTRODUCTION
The Mesolimbic Dopamine System
The mesocorticolimbic dopamine (DA) system originating in the ventral tegmental area
(VTA) and projecting to the nucleus accumbens (NAc) is considered to be a key area in reward
from natural behaviors such as feeding (Phillips et al., 2003), drinking (Agmo et al., 1995), and
drug reward, including alcohol reward (Koob, 1996). Figure 1 depicts the theoretical
connectivity of this pathway. Support for a role for this neural circuit in alcohol reward hinges on
the evidence demonstrating that local injections of DA antagonists into the NAc and/or afferent
circuit systems prevent ethanol self-administration in rats (Hyytia and Koob, 1995; Pettit et al.,
1984; Roberts et al., 1996; Vaccarino et al., 1985). Moreover, rats will self-administer ethanol
directly into the VTA (Gatto et al., 1994),
and an ethanol-induced increase of DA
release in the NAc, detected by
microdialysis, has been reported extensively
(Di Chiara and Imperato, 1988; Weiss et al.,
1993; Wozniak et al., 1991; Yoshimoto et
al., 1992). Acute ethanol increases the firing
rate of midbrain DA neurons both in vivo
and in vitro (Brodie et al., 1990a; Gessa et
al., 1985), and chronic ethanol reduces both

Figure 1: VTA DA and GABA Neurons Project to the
NAc via the Medial Forebrain Bundle (MFB). Direct
pathway NAc MSNs expressing D1 receptors project
back to the VTA and inhibit VTA GABA neurons.
While there are similarities between VTA GABA and
NAc MSNs their GLU and GABA and D1 and D2
receptor hodology differ appreciably.

DA activity and release of DA in the NAc during withdrawal (Diana et al., 1993).
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D2 Dopamine Receptors as Biomarkers for Brain Dopamine Levels
Dopamine neurons in the SN and VTA are inhibited by DA via D2 autoreceptor
activation (for review see (Adell &
Artigas, 2004)). Dopamine D2R
expression in DA neurons in the
midbrain that are involved in
movement (i.e., substantia nigra; SN)
and motivation (i.e., ventral
tegmental area; VTA) is a wellknown biomarker for brain DA
levels, drug abuse and dependence.
Currently, the levels of D2Rs in the

Figure 2: Chronic Ethanol Exposure Significantly Decreases
D2R Expression. Chronic ethanol mice also demonstrate
significant differences in TH expression, but for the intents and
purposes of this study, we focused on the relative mRNA
expression of the biomarker, D2.

brain can be studied with positron emission tomography (PET) and they correlate directly with
brain DA levels. Many animal and human studies have demonstrated convincingly that D2R
expression is directly proportional to DA levels in the brain with a lag of minutes to hours. The
chronic abuse of stimulant drugs reduces DA D2R levels throughout the mesolimbic system
(Figure 2) (Nader et al., 2002). Thus, D2Rs are highly responsive to brain DA levels. However,
PET scans are cost-prohibitive to be used in clinical practice. In addition to cost, invasiveness
and radiation risk preclude PET scans as a routine clinical tool for assessment of D2R levels.

2

Electrophysiology of Dopamine Release and Tie to D2R Expression
Using fast scan cyclic voltammetry (FSCV) in mice and rats, we have found that DA
release in the ventral striatum, the terminal region of VTA DA neurons, is reduced by
moderately intoxicating doses of ethanol and markedly enhanced by systemic administration of

:
Figure 3: Eticlopride and Ethanol’s Effects On Dopamine Release (A) Time course of DA release before and after
intraperitoneal eticlopride (ETIC; 1 mg/kg) and ethanol (EtOH) in a representative anesthetized rat. Note the marked
enhancement of DA release with eticlopride. The intensity of stimulation was adjusted (reduced) to produce control
levels of DA release (ADJ’d). Ethanol was injected intraperitoneally after eticlopride. Note that ethanol inhibited the
DA signal. (B) This graph summarizes the effects of ethanol (2.5 g/kg) on DA release in the NAc with and without
eticlopride. Eticlopride significantly increased while ethanol significantly decreased DA release. Eticlopride did not
significantly alter ethanol release. Values in ( ) represent n values to date.

D2R antagonists (e.g., eticlopride; Figure 3). The enhancement of DA release by eticlopride is
probably the most robust and reproducible effect we have observed in our studies of DA release.
As eticlopride significantly enhances DA release, it will be used as a positive control for the
studies outlined to evaluate D2R expression in the blood and brain associated with high levels of
DA release. In preliminary studies, we found that D2R expression in the VTA is enhanced by
eticlopride and reduced by ethanol, which is consistent with its well-known lag in DA release
(Figure 4).
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We also evaluated D2R expression in
WBCs of rodents. Using flow cytometry and
fluorescence immunocytochemistry, we have
found that ~13% of WBCs in both rats and mice
express D2Rs. Figure 5 shows D2R labeling in
some WBCs. Using multiple fluorophores for
different WBC types in mouse blood, we found
that most of the D2R+ WBCs are activated
monocytes. This is somewhat surprising
considering the existing literature suggesting that

Figure 4. Ethanol and Eticlopride-Induced Change in
D2R Expression: Preliminary. An intraperitoneal
injection of eticlopride enhances D2 mRNA
expression in the VTA while an IP dose of ethanol
reduces D2 mRNA expression with a time course of
1-2 hrs.

lymphocyt
es express
D2
receptors.

Figure 5: A Subpopulation of WBCs Express D2Rs. (A) Stain for all WBCs. (B) One of the WBCs
in (A) expresses D2Rs.

4

RATIONALE AND HYPOTHESES
Markers of D2R expression are not only detectable in the brain but are also expressed in
peripheral tissues, including blood, where DA appears to play a pivotal role in mediating
communication between the nervous and immune systems (Basu & Dasgupta, 2000), and in
particular via D2Rs on lymphocytes (Basu et al., 2010). Of particular relevance, D2/D3 receptor
expression is known to be enhanced in lymphocytes of schizophrenics (Ilani et al., 2001),
reduced in Alzheimer’s disease (Barbanti et al., 2000a), increased in migraineurs (Barbanti et al.,
2000b) and reduced in Parkinson’s patients (Nagai et al., 1996), albeit other DA receptors are
increased in Parkinson’s patients (Barbanti et al., 1999). Thus, it has been suggested that DA
receptor mRNA expression in circulating blood might reflect the DA receptor level in the brain
(Ilani et al., 2001) and might serve as a useful surrogate marker for more direct measurements of
central receptor status, and thus by extrapolation, DA levels in the brain (Gladkevich et al.,
2004). A recent study has found the D2Rs are expressed on WBCs in humans and that their
expression correlates robustly with psychostimulant use and cognitive deficits (Ersche et al.,
2011).
Critical DA-related gene products in the VTA, such as tyrosine hydroxylase (TH) are upregulated (Ortiz et al., 1995), and D2Rs are down-regulated (Rommelspacher et al., 1992), 24 hr
after withdrawal from chronic alcohol. We have shown that GABA neurons in the VTA, which
regulate the activity of DA neurons, are activated by DA (Stobbs et al., 2004; Lassen et al.,
2007) via D2 receptors (Steffensen et al., 2008) and that D2Rs are down-regulated in VTA
GABA neurons during withdrawal from chronic ethanol (Ludlow et al., 2009).
Thus, the specific aim of this study was to determine the time course of adaptations in
D2R expression and DA release in the mesolimbic DA system and in WBCs following systemic
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administration of drugs known to modify DA release and chronic D2R expression; mainly, the
D2R antagonist eticlopride, the D2R agonist quinpirole, and ethanol. The four experiments we
employed to test this hypothesis were: 1) Examine acute eticlopride (positive control), quinpirole
(negative control) and ethanol (addiction component) effects on DA release in the NAc and D2R
expression in WBCs in vivo sampled every hour for two hours; 2) Examine acute eticlopride,
quinpirole and ethanol effects on D2R expression in WBCs in vitro. This is the control
experiment for direct effects on WBC D2Rs; 3) Examine acute eticlopride, quinpirole and
ethanol effects on D2R expression in the VTA, NAc, temporal lobe cortex two hours after
injection (acute, non-dependent condition); 4) Evaluate baseline D2R expression in the VTA,
NAc and temporal lobe cortex sixteen hours after withdrawal from chronic intermittent ethanol
exposure (dependent condition) in the alcohol vapor chambers (chronic, dependent condition).
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MATERIALS AND METHODS
Animal Subjects and Surgical Procedure
Experimental protocols were approved by the Institutional Animal Care and Use
Committee (IACUC) of Brigham Young University, which meet or exceed NIH guidelines.
Adult male Wistar rats (PND 30-120) were used in this study. Once weaned at PND 21, all rats
were housed in groups of two-three per cage and placed on a reverse light/dark cycle with lights
ON from 8 PM to 8 AM. For DA FSCV recordings in vivo, rats were anesthetized using
Isoflurane (MWI Veterinary Supply, Boise, ID) and placed in a stereotaxic apparatus. Anesthesia
level was maintained at 1.5 % throughout the experiments. Body temperature was maintained at
37.4 ± 0.4 º C by a feedback regulated heating pad. With the skull exposed, we drilled trephine
holes for placement of stimulating and recording electrodes.
Carbon Fiber Electrodes and Fast Scan Cyclic Voltammetry
For voltammetry recordings in vivo, a 7.0 µm diameter carbon fiber was inserted into
borosilicate capillary tubing (1.2 mm o.d.; A-M Systems, Sequim, WA) under negative pressure
and subsequently pulled on a vertical pipette puller (Narishige, East Meadow, NY). The carbon
fiber electrode (CFE) was cut under microscopic control with 150 µm of bare fiber protruding
from the end of the glass micropipette. We back-filled the CFE with 3 M KCl. The electrode
potential was linearly scanned as a triangular waveform from -0.4 to 1.2 V and back to -0.4 V vs
Ag/AgCl using a scan rate of 400 V/s. Cyclic voltammograms were recorded at the carbon fiber
electrode every 100 msec (i.e., 10 Hz) by means of a ChemClamp voltage clamp amplifier
(Dagan Corporation, Minneapolis, MN). Voltammetric recordings were performed and analyzed
using LabVIEW (National Instruments, Austin, TX)-based customized software (Demon
Voltammetry, (Yorgason et al., 2011). Stimulations were performed periodically every 2 min in
7

vivo. Dopamine levels were monitored for a stabilization period typically lasting 20 min. Once
the stimulated DA response was stable for five successive collections, and did not vary by more
than 10%, baseline measurements were taken.
Stimulation and Recording
For in vivo DA recordings, mice were anesthetized with Isoflurane and placed in a
stereotaxic apparatus (David Kopf Instruments, Tejunga, CA). Bipolar, coated stainless steel
electrodes were stereotaxically implanted into the medial forebrain bundle (MFB; -2.5 P, +1.9 L,
-8.0-9.0 V), and a capillary glass-based CFE in the NAc core (+1.6 A, +1.9 L, -6.5-8.0 V). The
MFB was stimulated with 60 biphasic pulses at 60 Hz (4 msec pulse width) at 2 min intervals.
Stimulation and recording electrodes were positioned by fine stereotaxic control to optimize the
release of DA at 1.5 mA stimulation intensity.
Drug Preparation and Administration
For in vivo experiments, eticlopride hydrochloride (Sigma Aldrich, St. Louis MO) was
dissolved in physiological saline solution and administered at a dose of 1.0 mg/kg intravenously
(IV). Ethanol (Decon Labs Inc., King of Prussia, PA) was dissolved in like manner, but into
physiological saline solution at 16 % w/v and administered at a dose of 2.5 g/kg intraperitoneally
(IP). Finally, quinpirole hydrochloride (Sigma Aldrich, St. Louis MO) was dissolved into
physiological saline solution and administered at a dose of 0.1 mg/kg IV. These doses previously
demonstrated robust, physiologically relevant enhancement and inhibition of DA release
respectively.
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qRT-PCR Methods
mRNA Isolation: Tissue punches were taken at 1 mm2 from the VTA, NAc, and temporal
lobe cortex. These samples were taken from rats treated with eticlopride, quinpirole or ethanol
two hours post injection and also from saline–injected rats as a control. Samples were placed in
800ul of Trizol reagent (ThermoFischer Scientific, Waltham, MA) to halt mRNA degradation.
The mRNA was extracted by chloroform, ethanol washes and centrifugation following the Trizol
manufacturer’s protocol. The mRNA concentrations were measured using mass spectroscopy
and a reverse transcriptase reaction was run on the samples to convert the mRNA to cDNA.
qPCR: Two targets were examined by PCR, D2R as the varying gene of interest and 18S
as the reference gene. The primers are designed for each target along with FAM-TAMRA
primers for increased specificity. The samples were run for 60 cycles in triplicate.
Quantification: Quantification of the qPCR data was obtained using the ∆∆CT method.
Averages of the triplicates were taken and the cycle numbers for 18S were subtracted from the
D2R cycle numbers for each sample so they were comparable across samples. Average
expression was obtained for each sample and all groups were normalized to the saline group.
Brain Slice Preparation for Immunofluorescence
Under sodium pentobarbital anesthesia (80 mg/kg, IP), rats from one of the four
treatment groups were perfused with 100 ml of saline followed by 150-200 ml of 4 %
paraformaldehyde (PFA) (Sigma Aldrich, St. Louis MO). The brains were then harvested and
stored in 10 % sucrose and 4 % PFA solution at 4ºC overnight, and then transferred to 30 %
sucrose in 0.01M PBS for at least 48 hours. The fixed brains were then frozen in OCT compound
(Sakura Finetek USA, Inc., Torrence, CA) and coronal sections were taken at 30 µm using a
cryostat (ThermoFischer Scientific, Waltham, MA). Sections containing NAc, VTA, and
9

temporal lobe cortex were stored in 30 % ethylene glycol and 30 % glycerol in 0.01M PBS at
-20 ºC.
Staining Preparation and Imaging for D2R Immunofluorescence
Tissue samples were taken from the ethylene glycol, glycerol, and 0.01 M PBS solution
and washed three times in 0.01M PBS. Between each washing, the tissue samples were placed on
an Orbitron Rotator for five minutes (Boekel Scientific, Feasterville, PA). After washing,
blocking solution comprised of 4% normal goat serum (NGS) (Jackson Immunoresearch, West
Grove, PA), 0.1% Triton X-100 (ThermoFischer Scientific, Waltham, MA), and 0.1 % bovine
serum albumin (BSA) (Sigma Aldrich, St. Louis, MO) in 0.01 M PBS was added and samples
were placed on the orbitron for one hour at room temperature. Samples were then washed three
more times using the same technique mentioned previously. Following the wash, we added
500µL of primary antibody rabbit polyclonal IgG anti-D2 (AB5084P, Millipore Corporation,
Billerica, MA) at a dilution of 1:150 of the dilution buffer which consisted of 5ml 0.1M PBS,
5mg BSA, and 15 µL Triton X-100. Samples were placed on orbitron rotator overnight (at least
20 hours) at 4 ºC. After ample time for primary antibody binding, samples were washed three
times for ten minutes each time in 0.01 M PBS. The secondary antibody, Alexa Fluor 488 goat
anti-rabbit IgG (A11034, Invitrogen, ThermoFischer Scientific, Waltham, MA) was then added
at a dilution of 1:500 and samples were placed on orbitron for two hours at room temperature.
After secondary antibody binding, samples were washed three times for ten minutes each time
with 0.01 M PBS. The stained tissue slices were then mounted on microscope slides and
coverslip placed using Vectashield H-1000 mounting medium (Vector Laboratories, Burlingame,
CA). All secondary antibody staining procedures were performed in dimmed lighting to prevent
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photo-bleaching of the fluorescent antibody. Tissue was then viewed using an Olympus
Fluoview laser scanning confocal microscope (Olympus America, Center Valley, PA).
In Vitro Blood Experimentation Methods
Blood from naïve male rats was extracted using heparinized tubing and a heparinized
syringe from a catheter placed in the jugular vein. The extracted amount (800 µL) was then
placed in a heparinized 1.7 mL RNAse/DNAse-free Eppendorf tube (BioExpress, Kaysville,
UT). The extracted blood was then equally separated into 16 eppendorf tubes, each containing 50
µL of heparinized-blood and 95 0µL buffer composed of 1 % HEPES (Sigma Aldrich, St. Louis
MO), 10% fetal bovine serum (FBS) (Sigma Aldrich, St. Louis MO) and RPMI-1640 (Sigma
Aldrich, St. Louis MO) medium. The tubes were then centrifuged (5 kHz) at room temperature
for 15 min. After centrifuging, the plasma layer was decanted and the sample was resuspended in
950 µL of buffer solution. Then, the 16 tubes were separated into four treatment groups (saline,
ethanol, eticlopride, or quinpirole), each comprising of four tubes. Saline, ethanol, eticlopride
and quinpirole were all administered to their respective tubes at dosages that mirrored those of
the in vivo experiments, which were 250 mg%, 5 µM and 0.5 µM respectively. The tubes were
then incubated at 37 ºC for two hours. After incubation, all tubes were centrifuged for 15 min at
5 kHz, the most superficial layer was removed, and the remaining blood sample was resuspended
in 800 uL Trizol Reagent and taken directly to the -80 ºC freezer. mRNA isolation was
performed as per qRT-PCR Methods above.
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RESULTS
qRT-PCR Data for Brain Tissue and
Blood Analysis
We took 0.79 mm2 tissue punches
from the NAc, VTA, and temporal lobe
cortex of rats treated with saline, ethanol,
eticlopride or quinpirole. This was
accomplished by punching a 1 mm
diameter blunt needle through a 1 mm
thick tissue section. Using RT-PCR we
were able to determine the changes in

Figure 6: Characteristic qPCR Data for In Vivo Blood
Experiments. The red line represents the cycle number
(7) where 18S comes up and the blue line represents D2
(28). Subtracting the 18S cycle number from D2 yields
the ΔCt.

D2R expression between the four treatments two hours after injection. Figure 6 shows
representative qPCR data that illustrates typical cycle numbers where 18S and D2 are observed.
Figure 7 represents tissue punch D2R expression at the three regions of interest: NAc, VTA, and
temporal lobe cortex.
The VTA showed drastic changes in D2R expression between the treatment groups. The
ethanol treated animals demonstrated a 494 % increase in D2R expression relative to saline.
Eticlopride and quinpirole also showed marked changes in expression with eticlopride yielding a
36 % and quinpirole a 28 % increase in D2R expression. The NAc also demonstrated substantial,
rapid changes in receptor expression. Again, the ethanol-treated animals experienced an average
of 113 % increase in D2R expression, but eticlopride and quinpirole were merely 29 and 0.14 %,
respectively, relative to saline. Finally, in the cortex, drastic decreases in D2R expression were
seen in the ethanol and quinpirole treated animals with ethanol being 4.2 % and quinpirole being
1.3 % of saline expression levels.
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When looking to the periphery for
drug effects on D2R expression, we see
suggestive, but not statistically significant
changes in D2R expression from WBCs
of the in vivo experiments (Figure 8).
Reasoning behind why such significant
variation is seen in this experiment is
explained more in the discussion.
Lastly, concerning the in vitro
blood experiments, limited data suggests
D2R expression on WBCs rapidly adapts
even when communication between the
nervous and immune systems cannot take
place (Figure 9). Ethanol increased
expression by 92 %, eticlopride showed
no change, and quinpirole decreased by
53 % relative to saline controls.
Differences in Immunofluorescence
between Treatment Groups
We observed suggestive treatment
effects in both the VTA and NAc (Figures

Figure 7: Changes in D2R Expression between the VTA,
NAc, and Cortex using qPCR. The three graphs above
demonstrate changes in relative D2R expression 2hrs after
treatment with saline (SAL), ethanol (ETOH), eticlopride
(ETIC), or quinpirole (QUIN) based on location in the
brain. D2R expression in the VTA increased in the ethanol
and quinpirole groups compared to control. D2R
expression in the NAc increased in the ethanol group but
decreased in the eticlopride and quinpirole groups,
respectively. Finally, in the cortex, the ethanol and
quinpirole groups showed drastic decrease in D2R
expression.

10 and 11). In the VTA, animals treated with ethanol and eticlopride demonstrated an increased
amount of expression when compared to saline. Conversely, animals treated with quinpirole
showed a slightly decreased amount of expression. These findings correspond with the data
13

gathered above in the RT-PCR
portion of this project and suggest
that rapid adaptation of D2R is
occurring in the brain.

Figure 8: qPCR Quantification of Changes in Peripheral WBC D2R
Expression. All treatment groups showed decreases in D2R
expression 2hrs post injection.
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DISCUSSION
As shown in our results, in vivo and
in vitro D2R expression undergoes rapid
adaptation in the brain and blood when
exposed to acute doses of ethanol and
other D2R targeting drugs. The fact that
these changes were monitored using RTPCR, specifically in blood from in vivo
animals, suggests that peripheral D2R
expression could be a biomarker of brain

Figure 9: Changes in Peripheral D2R Expression from in
vitro Blood Experiments using qPCR. After 2 hrs of
incubation with treatment, ethanol increased, eticlopride
decreased, and quinpirole slightly increased D2R
expression.

DA levels. These findings are consistent with our preliminary electrophysiology data which
demonstrated ethanol, eticlopride, and quinpirole’s modulatory effects on brain DA levels.
The variation we observed in the blood experiments that was alluded to in the results was
partly due to difficulty gathering and analyzing the RT-PCR data. The 18S values obtained in
brain or blood tissue samples should be the same between experiments. In our case, the 18S
values showed considerable variation between experiments, even though the values themselves
were tight and accurate within experiments. Different methods of normalizing and analyzing this
data might lead to more conclusive evidence of how D2Rs are changing in the blood of in vivo
animals relative to the brain. Or, more effective, clean, and consistent methods of mRNA
isolation might also decrease the variability of 18S values between experiments.
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Tissue punch data revealed that in
the VTA, ethanol, eticlopride, and
quinpirole had a stimulatory effect on
D2R expression. In the NAc, ethanol
again increased D2R expression relative
to saline controls, but eticlopride and
quinpirole both decreased expression.
Finally, in the temporal lobe cortex,
ethanol and quinpirole had a significantly
inhibitory effect on D2R expression. The
purpose of using temporal lobe cortex
tissue punches was to have a control
reference for the NAc and VTA.

Figure 10: Immunofluorescence Differences in D2R
Expression in the VTA. Compared to saline treated
animals, ethanol and eticlopride animals displayed a
higher density of D2R expressing cells. This finding
corresponds with the data seen in the tissue punch RTPCR from above. Also, quinpirole treated animals
displayed similar density of D2R expressing cells relative
to saline. This finding also matches that of the tissue
punch RT-PCR data.

Unfortunately, this region of interest did not serve as that control. It is possible that D2Rs could
have different functional responsibilities depending on location in the brain and that is why
expression significantly changed. It is also possible that the punches were taken from what we
thought to be temporal lobe cortex, but in fact were from another brain location which might
utilize D2Rs in a way we are not familiar with.
Immunofluorescence (IF) also revealed changes in D2R expression in the brain. Our
findings regarding saline and ethanol correlated with that of RT-PCR and verified that the
changes we observed in these two treatment groups were consistent. There does appear to be
some discrepancies between the RT-PCR and IF data. For example, RT-PCR data showed little
change in D2R expression in the VTA of eticlopride treated rats while IF showed significant
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increase. Also, RT-PCR showed a
marked decreased in D2R expression in
the NAc of eticlopride treated animals
while IF showed similar, if not slightly
increased, expression. As of now, we
attribute this discrepancy to the small
sample size of the eticlopride (n=2) and
quinpirole (n=2) treated animals from
RT-PCR. Until more data is acquired for
these experiments, solid conclusions
cannot be made.
We are still in the process of

Figure 11: Immunofluorescence Differences in D2R
Expression in the NAc. Relative to saline, ethanol and
quinpirole increase D2R expression, while eticlopride
showed slight increase but remained relatively similar to
saline.

gathering and analyzing in vitro blood data. The current data (Figure 9) suggests that in the
absence of the nervous system, D2R expression on WBCs still adapts when exposed to drug
treatment. The purpose of this adaptation is still largely unknown. However, considering that
D2Rs are G-protein coupled receptors, binding of D2Rs on WBCs with agonists likely induce
second messenger signaling mechanisms that lead to activation or inactivation of the cell.
Indeed, activation of D2-like receptors enhances the production of interleukin-10, a cytokine that
negatively regulates the function of effector T-cells (Butarelli et. al, 2011). This could occur with
quinpirole activation of D2Rs. It may be that quinpirole binding leads to activated monocytes
which can invade the brain. We are puzzled why WBCs undergo such marked down-regulation
with eticlopride. This is contrary to what happens in the brain, at least with
immunofluorescence, which shows that eticlopride is up-regulating D2Rs. Unfortunately,
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mRNA expression does not seem to accurately reflect protein expression. For the intents and
purposes of this project, what really matters is protein expression. In future studies, we will
include double staining of D2Rs with neurons, astrocytes, microglia and other cell types to
identify the purpose for D2R adaptation and whether or not there is a neuro-immune interaction
dictating the changes that occur in the blood.
We are also in the treatment stage of acquiring animals chronically dependent on
ethanol. The apparatus for these experiments was in use by another colleague for another project,
which made acquiring this data before now impossible. When ready, animals will be sacrificed,
the brains and blood will be analyzed, and more concrete data will help us determine whether or
not peripheral D2Rs can be used as a biomarker of brain DA, as chronic ethanol treatment
typically results in lowered DA release during withdrawal. We will study the rats 16-24 hrs after
withdrawal from chronic ethanol exposure, which is the peak withdrawal period.
The main direction for this research is to find a strong, predictable correlation between
peripheral D2R expression and central DA levels. As of now, our data suggests that rapid
adaptation of D2Rs is occurring in WBCs in vivo and in vitro, but the discrepancy between brain
and blood D2R expression shown by RT-PCR and IF leaves peripheral D2R tracking as a limited
and potentially misleading method of monitoring brain DA levels. That being said, protein
expression shown in figures 10 and 11 of in vivo animals seems to be more reliable, and less
variant, than D2 mRNA levels in RT-PCR. Thus, IF data that shows an increase in D2R
expression in the VTA after ethanol and eticlopride, and increase of D2R expression in the NAc
after ethanol and quinpirole provides the most compelling evidence for rapid adaptation of D2Rs.
On a broad level, this project contributes to the existing literature which states that
peripheral D2Rs are a potential biomarker for brain DA. This is the first demonstration of how
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acute ethanol exposure is rapidly modulating D2R expression in the VTA, NAc, and WBCs as
opposed to disease states and chronic drug abuse changing D2R expression. This project gives
suggestive evidence for rapid adaptation of D2Rs in the brain and blood in response to drugs of
abuse. Granted, addiction is not mediated by one receptor subtype alone, and the mechanisms
behind addiction are substantially more complex, but D2R monitoring could provide clues for
trends in addiction and treatment possibilities. The details of how cost-effective, accurate, and
clinically useful it would be to track changing D2R levels via qPCR are still unknown, but it
seems to be a more promising alternative to the current method of PET scanning.
Concerns, Pitfalls, Limitations and Alternative Approaches
For all of my experiments (tissue punches, blood mRNA analysis, immunofluorescence
(IF), in vitro blood analysis), I had to learn and use new techniques. The research that sparked my
interest in D2Rs came from findings using electrophysiology and DA neurochemistry in the brain.
Almost all of my experiments utilized non-electrophysiological and neurochemical techniques and
half of the experiments focused on D2Rs in the blood, or periphery. I am grateful this project required
me to learn new techniques, but one consequence was that gathering meaningful data took more time,
practice and patience than anticipated.
For example, for the in vivo tissue punch and blood mRNA experiments, my initial samples
were frequently contaminated, which prevented the RT-PCR from yielding useful data. After
troubleshooting my isolation technique and limiting variables that could introduce
contamination, I was able to gather adequate, but not convincing, data.
Concerning IF, staining for membrane versus cytosolic proteins proved more difficult
than anticipated. After changing our staining protocol several times and trying a new primary

19

antibody, we finally acquired the results we wanted. Now we need to perform additional
experiments.
The technical difficulties we experienced also revealed conceptual limitations. It is clear
that rapid adaptation occurred at two hours in both brain and blood samples, but could the
adaptation be stronger at four or six hours? The literature on D2 expression makes it clear that,
with chronic drug use, the strongest effect will occur days to weeks after treatment begins. One
alternative approach would be to test D2 expression at several time intervals between two and
ten hours to see when the maximum effect occurs.
One significant conceptual limitation that was not addressed by this project was the
purpose of rapid adaptation of D2Rs in the periphery. Moving forward, double staining of brain
tissue to show precisely where D2Rs are expressed under treatment conditions could lend
insight to the reason for rapid adaptation in the brain and blood. Staining for D2Rs on
astrocytes, activated microglia, and other types of cells before and after acute drug exposure
could provide clues for why D2R adaptation occurs.
My final concern is whether we chose the best approach for testing D2R adaptation in
the brain and blood. Concurrent western blots on central and peripheral D2R expression in
addition to RT-PCR might have provided verification of the effect we saw and explained some
of the variance. Fluorescence activated cell sorting can also be used to quantify changes in D2R
expression, but changes in fluorescence are not as descriptive as numerical changes acquired
using RT-PCR. Based off of methods in the literature and how others are testing D2R
expression, I think we chose the best possible method.
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